14845
document
Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial . The Nutritional Prevention of Cancer Trial was a double-blind , randomized , placebo-controlled clinical trial designed to test whether selenium as selenized yeast ( 200 microg daily ) could prevent nonmelanoma skin cancer among 1312 patients from the Eastern United States who had previously had this disease . Results from September 15 , 1983 , through December 31 , 1993 , showed no association between treatment and the incidence of basal and squamous cell carcinomas of the skin . This report summarizes the entire blinded treatment period , which ended on January 31 , 1996 . The association between treatment and time to first nonmelanoma skin cancer diagnosis and between treatment and time to multiple skin tumors overall and within subgroups , defined by baseline characteristics , was evaluated . Although results through the entire blinded period continued to show that selenium supplementation was not statistically significantly associated with the risk of basal cell carcinoma ( hazard ratio [ HR ] = 1.09 , 95 % confidence interval [ CI ] = 0.94 to 1.26 ) , selenium supplementation was associated with statistically significantly elevated risk of squamous cell carcinoma ( HR = 1.25 , 95 % CI = 1.03 to 1.51 ) and of total nonmelanoma skin cancer ( HR = 1.17 , 95 % CI = 1.02 to 1.34 ) . Results from the Nutritional Prevention of Cancer Trial conducted among individuals at high risk of nonmelanoma skin cancer continue to demonstrate that selenium supplementation is ineffective at preventing basal cell carcinoma and that it increases the risk of squamous cell carcinoma and total nonmelanoma skin cancer .
14846
Intervention_Pharmacological
Selenium supplementation
14847
Intervention_Other
secondary prevention
14848
Intervention_Control
placebo-controlled
14849
Intervention_Pharmacological
selenium as selenized yeast
14850
Intervention_Pharmacological
selenium supplementation
14851
Intervention_Pharmacological
selenium supplementation
14852
Intervention_Pharmacological
selenium supplementation
14853
Outcome_Physical
basal and squamous cell carcinomas of the skin
14854
Outcome_Physical
time to first nonmelanoma skin cancer diagnosis
14855
Outcome_Physical
time to multiple skin tumors
14856
Outcome_Physical
risk of basal cell carcinoma
14857
Outcome_Physical
elevated risk of squamous cell carcinoma
14858
Outcome_Physical
total nonmelanoma skin cancer
14859
Outcome_Physical
basal cell carcinoma
14860
Outcome_Physical
squamous cell carcinoma
14861
Outcome_Physical
total nonmelanoma skin cancer .
14862
Participant_Condition
nonmelanoma skin cancer
14863
Participant_Condition
nonmelanoma skin cancer
14864
Participant_Sample-size
1312
14865
Participant_Condition
Eastern United States
14866
Participant_Condition
previously had this disease